SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model
Abstract Polycystic ovary syndrome (PCOS) is a common endocrine, reproductive, and metabolic disorder affecting females. The management of PCOS is challenging and current interventions are not enough to deal with all consequences of this syndrome. We explored the beneficial effect of combined sodium...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-11-01
|
| Series: | Physiological Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.14814/phy2.15858 |
| _version_ | 1827632104474673152 |
|---|---|
| author | Manal Moustafa Mahmoud Laila Ahmed Rashed Somia Abdulatif Soliman Safaa Mostafa Sayed Omneya Kamel Samaa Samir Kamar Rania El Sayed Hussien |
| author_facet | Manal Moustafa Mahmoud Laila Ahmed Rashed Somia Abdulatif Soliman Safaa Mostafa Sayed Omneya Kamel Samaa Samir Kamar Rania El Sayed Hussien |
| author_sort | Manal Moustafa Mahmoud |
| collection | DOAJ |
| description | Abstract Polycystic ovary syndrome (PCOS) is a common endocrine, reproductive, and metabolic disorder affecting females. The management of PCOS is challenging and current interventions are not enough to deal with all consequences of this syndrome. We explored the beneficial effect of combined sodium glucose co transporter‐2 inhibitor (SGLT‐2i); (empagliflozin) and metformin on hormonal and metabolic parameters in an animal model of PCOS and insulin resistance (IR). Forty adult female Wistar rats divided into five groups: control, PCOS‐IR, PCOS‐IR treated with metformin, PCOS‐IR treated with empagliflozin, and PCOS‐IR treated with combined metformin and empagliflozin. Single modality treatment with metformin or empagliflozin yielded significant improvement in body mass index, insulin resistance, lipid profile, sex hormones, inflammatory markers, and ovarian cystic follicles. Combined metformin with empagliflozin expressed further significant improvement in sex hormones, inflammatory markers with disappearance of ovarian cystic follicles. The superior significant improvement with combined treatment over the single modality was in line with significant improvement in the ovarian AMPKα‐SIRT1 expression. |
| first_indexed | 2024-03-09T14:31:27Z |
| format | Article |
| id | doaj.art-1a232c3ae26a4ab98f6df331ce0382ba |
| institution | Directory Open Access Journal |
| issn | 2051-817X |
| language | English |
| last_indexed | 2024-03-09T14:31:27Z |
| publishDate | 2023-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Physiological Reports |
| spelling | doaj.art-1a232c3ae26a4ab98f6df331ce0382ba2023-11-28T00:21:19ZengWileyPhysiological Reports2051-817X2023-11-011122n/an/a10.14814/phy2.15858SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS modelManal Moustafa Mahmoud0Laila Ahmed Rashed1Somia Abdulatif Soliman2Safaa Mostafa Sayed3Omneya Kamel4Samaa Samir Kamar5Rania El Sayed Hussien6Department of Physiology, Faculty of Medicine Cairo University Cairo EgyptDepartment of Biochemistry Faculty of Medicine Cairo University Cairo EgyptDepartment of Pathology, Faculty of Medicine Cairo University Cairo EgyptDepartment of Physiology, School of Medicine New Giza University Cairo EgyptDepartment of Physiology, School of Medicine New Giza University Cairo EgyptDepartment of Histology, Faculty of Medicine Cairo University Cairo EgyptDepartment of Biochemistry Faculty of Medicine Cairo University Cairo EgyptAbstract Polycystic ovary syndrome (PCOS) is a common endocrine, reproductive, and metabolic disorder affecting females. The management of PCOS is challenging and current interventions are not enough to deal with all consequences of this syndrome. We explored the beneficial effect of combined sodium glucose co transporter‐2 inhibitor (SGLT‐2i); (empagliflozin) and metformin on hormonal and metabolic parameters in an animal model of PCOS and insulin resistance (IR). Forty adult female Wistar rats divided into five groups: control, PCOS‐IR, PCOS‐IR treated with metformin, PCOS‐IR treated with empagliflozin, and PCOS‐IR treated with combined metformin and empagliflozin. Single modality treatment with metformin or empagliflozin yielded significant improvement in body mass index, insulin resistance, lipid profile, sex hormones, inflammatory markers, and ovarian cystic follicles. Combined metformin with empagliflozin expressed further significant improvement in sex hormones, inflammatory markers with disappearance of ovarian cystic follicles. The superior significant improvement with combined treatment over the single modality was in line with significant improvement in the ovarian AMPKα‐SIRT1 expression.https://doi.org/10.14814/phy2.15858AMPKα‐SIRT1empagliflozininsulin resistancemetforminPCOS |
| spellingShingle | Manal Moustafa Mahmoud Laila Ahmed Rashed Somia Abdulatif Soliman Safaa Mostafa Sayed Omneya Kamel Samaa Samir Kamar Rania El Sayed Hussien SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model Physiological Reports AMPKα‐SIRT1 empagliflozin insulin resistance metformin PCOS |
| title | SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model |
| title_full | SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model |
| title_fullStr | SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model |
| title_full_unstemmed | SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model |
| title_short | SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model |
| title_sort | sglt 2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat pcos model |
| topic | AMPKα‐SIRT1 empagliflozin insulin resistance metformin PCOS |
| url | https://doi.org/10.14814/phy2.15858 |
| work_keys_str_mv | AT manalmoustafamahmoud sglt2inhibitorsenhancetheeffectofmetformintoamelioratehormonalchangesandinflammatorymarkersinaratpcosmodel AT lailaahmedrashed sglt2inhibitorsenhancetheeffectofmetformintoamelioratehormonalchangesandinflammatorymarkersinaratpcosmodel AT somiaabdulatifsoliman sglt2inhibitorsenhancetheeffectofmetformintoamelioratehormonalchangesandinflammatorymarkersinaratpcosmodel AT safaamostafasayed sglt2inhibitorsenhancetheeffectofmetformintoamelioratehormonalchangesandinflammatorymarkersinaratpcosmodel AT omneyakamel sglt2inhibitorsenhancetheeffectofmetformintoamelioratehormonalchangesandinflammatorymarkersinaratpcosmodel AT samaasamirkamar sglt2inhibitorsenhancetheeffectofmetformintoamelioratehormonalchangesandinflammatorymarkersinaratpcosmodel AT raniaelsayedhussien sglt2inhibitorsenhancetheeffectofmetformintoamelioratehormonalchangesandinflammatorymarkersinaratpcosmodel |